Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
David Miles(Guy's Hospital), Hamdy Abdel Azeem, Fabio Puglisi(University of Udine), Igor Bondarenko(Dnipro State Medical University), Q. Zhang, F. Puglisi(University of Udine), Bruno Coudert(Ludwig Boltzmann Institute for Cancer Research), Filippo Montemurro(Roche (Switzerland)), Isabelle Desmoulins(UniCancer Group), Sophie Barrett, Xiaoyu Hu(Shandong First Medical University), Peter C. Trask(Pfizer (United States)), Gustavo Ismael, Bella Kaufman(NYU Langone Health), Juan Antonio Matus, Claudia Peña-Murillo(Roche (Switzerland)), Véronique Dièras(Institut Curie), Francesco Ricci(Istituto Dermopatico dell'Immacolata), Florence Dalenc(Institut Claudius Regaud), Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Haralabos P. Kalofonos(University of Patras), Dirk Klingbiel(Max Planck Society), K. Bouzid, Claudia Andreetta(Ospedale Santa Maria della Misericordia di Udine), Yolande Du Toit(Roche (Switzerland)), Mario Campone(Institut de Cancérologie de l'Ouest), Max S. Mano, Valentine Revelant(Roche (Switzerland)), Eva Ciruelos Gil(Hospital Universitario 12 De Octubre), Eva Ciruelos(Hospital Universitario 12 De Octubre), Jean-Louis Merot, Ana Filipa Ferreira, Dimitriοs Mavroudis(University of Crete), I. Głogowska(Roche (Switzerland)), C. Beato(Centre Léon Bérard), Tamar Peretz‐Yablonski(Hadassah Medical Center), Shani Paluch–Shimon(Hebrew University of Jerusalem), C. Villarreal Garza(Centre Léon Bérard), Hassan Errihani
Cited by 92
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k